HB 556 would substantially narrow Maryland’s criminal prohibitions on drug paraphernalia by repealing the specific ban on using, possessing with intent to use, delivering, selling, manufacturing, or possessing with intent to deliver paraphernalia for injecting, ingesting, inhaling, or otherwise introducing controlled dangerous substances into the human body. In practical terms, the bill removes the “administration” portion of the paraphernalia offense while leaving in place prohibitions tied to paraphernalia used to plant, grow, process, package, store, or conceal controlled dangerous substances.
The bill also revises the definition of “controlled paraphernalia” by deleting hypodermic syringes, needles, and similar injection devices from that definition. In addition, it changes the controlled-paraphernalia offense so that it applies to paraphernalia associated with manufacturing, distributing, or dispensing controlled dangerous substances, rather than administering them, and it updates the list of items that may indicate unlawful intent. Across these sections, the bill reduces the maximum penalties for several paraphernalia offenses, generally lowering imprisonment exposure from multiple years to one year and reducing fines from higher amounts to $1,000 in the amended provisions. The bill is scheduled to take effect October 1, 2025.
The overall sentiment reflected by the bill itself is reform-oriented and decriminalizing, focusing on reducing criminal penalties and removing certain injection-related paraphernalia from the scope of the law. Because there are no committee transcripts or recorded votes provided, there is no direct evidence in the supplied materials of support or opposition from legislators, advocates, or the public.
The main point of contention likely concerns the policy choice to decriminalize or reduce penalties for paraphernalia associated with drug use, especially syringes and needles. Supporters would likely view the bill as a harm-reduction measure and a way to avoid criminalizing possession of items used in substance-use treatment or overdose prevention, while critics may argue it weakens enforcement tools against drug use and trafficking. The bill’s changes to the controlled-paraphernalia statute, including the shift from “administering” to “manufacturing, distributing, or dispensing,” are the most significant legal and policy changes.
HB 556 amends Maryland’s Criminal Law Article, especially the state’s drug paraphernalia provisions, by removing criminal liability tied specifically to paraphernalia used to inject, ingest, inhale, or otherwise introduce controlled dangerous substances into the body. It also removes hypodermic syringes, needles, and similar injection devices from the statutory definition of “controlled paraphernalia,” and lowers the maximum penalties for several paraphernalia offenses. The bill narrows the scope of conduct covered by the paraphernalia laws while preserving prohibitions related to manufacturing, distributing, storing, or concealing controlled substances.
The bill’s text reflects a clear decriminalization and harm-reduction approach, suggesting a generally reform-minded intent. However, because no committee testimony or vote record is included, the supplied materials do not show a documented legislative consensus or opposition. The available context therefore indicates the bill was introduced as a policy change, but not how it was received in committee or on the floor.
The likely controversy centers on whether removing injection-related paraphernalia from criminal prohibition will reduce harm and improve public health, or instead make it harder to deter drug use and related offenses. Another point of contention is the reduction in penalties for paraphernalia offenses, which opponents may view as too lenient. The most sensitive issue is the deletion of syringes and needles from “controlled paraphernalia,” since that change directly affects enforcement, syringe access, and treatment-related possession.